Patents by Inventor Jacqueline M. Mason

Jacqueline M. Mason has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies for inhibition of polo-like kinase 4
    Patent number: 12109215
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: October 8, 2024
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Jacqueline M. Mason, Mark R. Bray, Tak Wah Mak, Graham Fletcher
  • LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR
    Publication number: 20240150462
    Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.
    Type: Application
    Filed: March 11, 2022
    Publication date: May 9, 2024
    Inventors: Richard BROKX, Jacqueline M. MASON, Mark Robert BRAY, Gordon S. DUNCAN
  • COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE
    Publication number: 20230390294
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: August 18, 2023
    Publication date: December 7, 2023
    Inventors: Mark Robert Bray, Jacqueline M. Mason, Tak Wah Mak, Graham Fletcher
  • Combination therapies for inhibition of TTK protein kinase
    Patent number: 11766437
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: September 26, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Mark Robert Bray, Jacqueline M. Mason, Tak W. Mak, Graham Fletcher
  • COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
    Publication number: 20230165871
    Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-linhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 1, 2023
    Inventors: Graham Fletcher, Jacqueline M. Mason, Mark R. Bray
  • METHODS FOR TREATING CYTOKINE RELEASE SYNDROME
    Publication number: 20230144869
    Abstract: Disclosed herein is a method of treating a subject with aberrant cytokine release from a disease or condition or at risk of developing aberrant cytokine release from a disease or condition. The method comprises administering to the subject an effective amount of a compound represented by structural formula (I): (I) or a pharmaceutically acceptable salt thereof. The variables in structural formula (I) are as described herein.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 11, 2023
    Inventors: Mark R. Bray, Jacqueline M. Mason, Xin Wei, Gordon Duncan
  • TREATMENT FOR ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME
    Publication number: 20230010772
    Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 12, 2023
    Inventors: Mark R. Bray, Jacqueline M. Mason, Graham Fletcher
  • TSG-6 ANTIBODIES AND USES THEREFOR
    Publication number: 20220153834
    Abstract: The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: March 11, 2020
    Publication date: May 19, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • FCMR-Binding Molecules and Uses Thereof
    Publication number: 20220089725
    Abstract: The invention provides novel anti-FCMR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
    Type: Application
    Filed: February 14, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • LILRB3-BINDING MOLECULES AND USES THEREFOR
    Publication number: 20220089723
    Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation This invention can also be used to modulate osteoclast differentiation.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 24, 2022
    Inventors: Richard Brokx, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20210261554
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: December 26, 2020
    Publication date: August 26, 2021
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4
    Publication number: 20210060026
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 4, 2021
    Inventors: Jacqueline M. Mason, Mark R. Bray, Tak Wah Mak, Graham Fletcher
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10875863
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE
    Publication number: 20200230144
    Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
    Type: Application
    Filed: August 1, 2018
    Publication date: July 23, 2020
    Inventors: Mark Robert Bray, Jacqueline M. Mason, Tak W. Mak, Graham Fletcher
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20190225617
    Abstract: The invention is a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: January 28, 2019
    Publication date: July 25, 2019
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-Wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 inhibitors and method of treating cancer with same
    Patent number: 10239881
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 26, 2019
    Assignee: University Health Network
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray
  • RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
    Publication number: 20180282335
    Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).
    Type: Application
    Filed: October 9, 2015
    Publication date: October 4, 2018
    Inventors: Radoslaw Laufer, Grace Ng, Richard Brokx, Heinz W. Pauls, Sze-wan Li, Jacqueline M. Mason, Mark R. Bray
  • Treatment for pancreatic cancer
    Patent number: 9642856
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 9, 2017
    Assignee: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray
  • Treatment for pancreatic cancer
    Patent number: 9555042
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 31, 2017
    Assignee: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray
  • TREATMENT FOR PANCREATIC CANCER
    Publication number: 20160250220
    Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2014
    Publication date: September 1, 2016
    Applicant: University Health Network
    Inventors: David W. Hedley, Ines Lohse, Jacqueline M. Mason, Mark R. Bray